Physician profile
John C Cates
NPI 1558333146
$2,271.17
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $463 · 2020: $739 · 2021: $423 · 2022: $462 · 2023: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $183.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $506.69 | 2020-2023 | Breztri, Farxiga |
| Glaxosmithkline, LLC. | $212.69 | 2019-2023 | Trelegy Ellipta |
| Novo Nordisk INC | $209.31 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $181.72 | 2019-2021 | |
| Amarin Pharma, INC. | $157.12 | 2019-2021 | |
| Lilly USA, LLC | $137.19 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $127.62 | 2019-2021 | |
| Allergan, INC. | $109.76 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $109.02 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.14 | 2019-2021 | |
| Abbvie INC. | $92.83 | 2019-2022 | |
| Pfizer INC. | $79.87 | 2019-2023 | |
| Eisai INC. | $60.65 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $53.59 | 2020 | |
| Sanofi-Aventis U.S. LLC | $53.34 | 2019-2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $22.86 | 2022 | |
| Amgen INC. | $18.71 | 2019 | |
| Nestle Healthcare Nutrition INC. | $17.28 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $12.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.